Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Cholelithiasis (gallstones) was reported at low rates in the Phase 2 trial Incidence was slightly higher in higher-dose groups, though absolute numbers were small This observation is not unique to retatrutide semaglutide and tirzepatide trials also reported gallbladder events Cardiovascular Observations Heart rate changes were documented in clinical trial participants: Small mean increases in heart rate (2-4 bpm) were observed in active treatment groups This is consistent with GLP-1 agonist class effects semaglutide and tirzepatide produce similar heart rate increases No increased rate of major adverse cardiovascular events (MACE) was observed in Phase 2 TRIUMPH-4 is specifically designed to evaluate cardiovascular outcomes at scale Injection Site Reactions As a subcutaneous injectable, injection site reactions were reported: Injection site erythema, pain, and pruritus were documented at low rates Most injection site events were Grade 1 (mild) No injection site reactions led to treatment discontinuation in published data How Retatrutide Adverse Events Compare to Other GLP-1 Compounds Comparing adverse event profiles across different trials has significant limitations patient populations, dose ranges, and endpoint definitions vary
pH The term "pH" serves as a descriptor for the hydrogen ion active concentration in a solution or, alternately, the degree of acidity or alkalinity therein
The added glucagon receptor activity is a key research distinction, not a reason to self-select one treatment over another
They make it easier to feel full, eat less, and cut cravings, while also helping keep blood sugar steady for long-term weight support
Maintenance-Free : Features a fully enclosed, fan less design that prevents particle ingress, ensuring reliable performance with minimal upkeep
95% CI: 0.8, 0.9
